Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
EV/EBITDA has expanded 62.3% YoY to 27.6x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 34.29 | — | — | 11.17 | 18.60 | 25.68 | 31.95 | 37.42 | 47.47 | 219.14 | 105.33 | 74.72 | 93.50 |
| — | — | — | -70.1% | -60.8% | -88.3% | -69.7% | -49.9% | -49.2% | — | — | -45.9% | +200.8% | |
| P/S Ratio | 3.68 | 3.35 | 3.35 | 3.27 | 4.66 | 4.32 | 4.65 | 5.80 | 6.71 | 7.16 | 7.27 | 7.10 | 7.92 |
| — | -22.4% | -27.9% | -43.5% | -30.5% | -39.6% | -36.1% | -18.4% | -15.4% | -20.1% | -6.5% | -2.4% | +9.5% | |
| P/B Ratio | 2.00 | 1.93 | 1.72 | 1.79 | 2.40 | 2.28 | 2.56 | 3.12 | 3.43 | 3.74 | 3.45 | 3.53 | 4.06 |
| — | -15.6% | -32.9% | -42.6% | -30.1% | -38.9% | -25.9% | -11.6% | -15.4% | -10.7% | +0.3% | +2.5% | +18.6% | |
| P/FCF | 16.36 | 49.77 | 7.64 | 16.07 | 22.03 | 19.54 | 17.30 | 42.58 | 338.14 | — | 37.68 | 89.28 | — |
| — | +154.7% | -55.8% | -62.3% | -93.5% | — | -54.1% | -52.3% | — | — | +16.7% | -35.2% | — | |
| EV / EBITDA | 18.18 | 27.59 | — | 8.63 | 13.66 | 17.00 | 25.93 | 28.31 | 38.32 | 114.64 | 76.61 | 47.54 | 54.64 |
| — | +62.3% | — | -69.5% | -64.3% | -85.2% | -66.2% | -40.5% | -29.9% | -99.9% | -57.3% | -23.5% | +132.0% | |
| EV / EBIT | — | 175.16 | — | 8.48 | 13.95 | 18.30 | 25.08 | 30.64 | 40.68 | 189.66 | 94.75 | 58.01 | 80.27 |
| — | +857.2% | — | -72.3% | -65.7% | -90.4% | -73.5% | -47.2% | -49.3% | — | -93.5% | -43.9% | +185.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
BioMarin Pharmaceutical Inc.'s operating margin was 9.1% in Q4 2025, up 15.1 pp QoQ and down 12.5 pp YoY. The trailing four-quarter average of 16.7% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 19.0% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.1% | 66.3% | 82.0% | 81.8% | 79.7% | 81.8% | 74.7% | 81.7% | 80.7% | 79.0% | 78.0% | 78.1% | 77.3% |
| — | -19.0% | +9.7% | +0.2% | -1.3% | +3.5% | -4.2% | +4.6% | +4.4% | +3.6% | +1.3% | +1.5% | -0.2% | |
| Operating Margin | 16.6% | 9.1% | -6.0% | 33.5% | 30.0% | 21.6% | 15.3% | 16.9% | 13.6% | 2.2% | 5.3% | 11.0% | 10.5% |
| — | -58.0% | -139.4% | +98.3% | +120.4% | +881.6% | +190.9% | +53.6% | +30.3% | +148.3% | +1197.8% | +50.2% | -60.4% | |
| Net Margin | 10.8% | -5.3% | -4.0% | 29.1% | 24.9% | 16.7% | 14.2% | 15.1% | 13.7% | 3.2% | 6.9% | 9.4% | 8.5% |
| — | -131.9% | -127.8% | +93.6% | +82.4% | +430.3% | +104.8% | +59.9% | +60.3% | +6909.9% | +627.7% | +81.7% | -63.3% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.7% | -0.8% | -0.5% | 4.1% | 3.2% | 2.3% | 2.0% | 2.1% | 1.8% | 0.4% | 0.8% | 1.2% | 1.1% |
| — | -134.0% | -125.7% | +96.7% | +83.3% | +445.4% | +137.7% | +74.3% | +61.1% | +7763.0% | +669.1% | +90.9% | -60.7% | |
| ROA | 4.6% | -0.6% | -0.4% | 3.3% | 2.6% | 1.8% | 1.5% | 1.5% | 1.3% | 0.3% | 0.6% | 0.9% | 0.8% |
| — | -133.9% | -126.8% | +114.2% | +103.2% | +502.6% | +151.5% | +78.3% | +62.8% | +7782.1% | +665.5% | +90.3% | -60.3% | |
| ROIC | 7.4% | 1.1% | -0.6% | 3.9% | 3.1% | 2.3% | 1.6% | 1.7% | 1.2% | 0.2% | 0.4% | 0.9% | 0.9% |
| — | -51.4% | -140.7% | +131.4% | +154.3% | +1018.4% | +260.4% | +75.5% | +34.2% | +154.6% | +1301.1% | +59.4% | -56.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
BioMarin Pharmaceutical Inc.'s Debt/EBITDA ratio is 6.0x — elevated, raising questions about debt serviceability.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.21 | 0.22 | 0.22 | 0.22 | 0.23 | 0.23 |
| — | -7.9% | -10.4% | -51.8% | -51.9% | -51.9% | -50.2% | -9.0% | -7.9% | -6.8% | -6.4% | -5.7% | -5.5% | |
| Debt / EBITDA | 0.97 | 5.98 | — | 2.04 | 2.45 | 3.26 | 4.53 | 7.48 | 9.47 | 26.67 | 19.49 | 12.02 | 12.31 |
| — | +83.6% | — | -72.7% | -74.2% | -87.8% | -76.7% | -37.7% | -23.1% | -99.9% | -60.0% | -29.1% | +85.8% | |
| Current Ratio | 5.21 | 5.21 | 4.83 | 5.56 | 5.52 | 5.33 | 4.27 | 3.05 | 2.74 | 2.51 | 2.54 | 4.94 | 4.75 |
| — | -2.2% | +13.0% | +82.1% | +101.2% | +112.0% | +68.1% | -38.2% | -42.2% | -46.2% | -50.7% | -8.8% | -2.7% | |
| Quick Ratio | 3.50 | 3.50 | 3.10 | 3.60 | 3.49 | 3.29 | 2.62 | 1.95 | 1.70 | 1.57 | 1.65 | 3.31 | 3.21 |
| — | +6.2% | +18.0% | +85.2% | +105.6% | +109.7% | +58.7% | -41.2% | -47.2% | -50.2% | -53.3% | -10.4% | -1.9% | |
| Interest Coverage | 48.95 | 28.58 | -18.10 | 103.35 | 78.20 | 62.63 | 38.37 | 33.70 | 24.94 | 2.33 | 8.08 | 17.46 | 16.85 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonBioMarin Pharmaceutical Inc.'s current P/E is 34.3x. The average P/E over the last 2 quarters is 14.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
BioMarin Pharmaceutical Inc.'s current operating margin is 16.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BioMarin Pharmaceutical Inc.'s business trajectory between earnings reports.